ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1398

Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis

Alojzija Hocevar1, Rok Jese1, Jelka Kramaric2, Matija Tomšič3 and Ziga Rotar3, 1UKC Ljubjana, Ljubjana, Slovenia, 2UKC Ljubjana, Ljubjana, 3Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia

Meeting: ACR Convergence 2021

Keywords: Adrenal insufficiency, giant cell arteritis, glucocorticoids

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Adrenal insufficiency is frequently neglected and underappreciated complication of systemic glucocorticoid therapy. We aimed to evaluate the prevalence of glucocorticoid induced adrenal insufficiency in giant cell arteritis (GCA).

Methods: We analysed adrenal function data in a cohort of GCA patients (51 (67.1%) females, median (IQR) age 72.9 (66.3-77.4) years) in whom a discontinuation of methylprednisolone therapy was planned. Adrenal function was tested by Corticotropin (Synacthen®) stimulation test (CST). To perform the CST, methylprednisolone was substituted with hydrocortisone (20mg qd in three divided doses) for one to four weeks before the test. Adrenal insufficiency was defined as cortisol level < 450 nmol/l measured 30 minutes after the corticotropin injection; additionally, the result of the CST was defined as borderline when the cortisol level 30 minutes after corticotropin injection was between 450 nmol/l and 500 nmol/l.

Results: Adrenal function was tested in 76 GCA patients before definite methylprednisolone withdrawal (after a median 13.5 (12.9 – 24.6) months of glucocorticoid therapy). The mean (SD) methylprednisolone dose, prior to substitution with hydrocortisone and subsequent CST, was 3.7 (0.9) mg. Adrenal insufficiency was detected in 37/76 patients (48.7%); additionally, 10/76 patients (13.2%) had a borderline CST result. Twenty-two patients with either adrenal insufficiency or borderline CST result, had a repeated CST after a median (IQR) 11.6 (8.1; 13.3) months. Adrenal insufficiency persisted in 12/22 (54.5%) patients and was borderline in one patient (4.5%). In 9/22 (40.9%) patients adrenal function recovered meanwhile. A third CST was performed in 6/13 patients with abnormal second CST after median (IQR) 8.3 (6.9; 12.6) months. Adrenal function recovered in one patient, while insufficiency persisted in the remaining 5 patients.

Conclusion: Adrenal insufficiency is frequent and potentially long-lasting glucocorticoid induced adverse event in GCA patients.


Disclosures: A. Hocevar, None; R. Jese, None; J. Kramaric, None; M. Tomšič, None; Z. Rotar, None.

To cite this abstract in AMA style:

Hocevar A, Jese R, Kramaric J, Tomšič M, Rotar Z. Adrenal Insufficiency After Glucocorticoid Treatment of Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/adrenal-insufficiency-after-glucocorticoid-treatment-of-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adrenal-insufficiency-after-glucocorticoid-treatment-of-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology